Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (282)	4/10/1999 12:17:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 810

Rick, you have pointed out a couple things regarding Onyx recently on other threads... I appreciate you taking the time to help lead me to the right questions, but I could use a couple of clarifications-- You once posed to Larry on the tfif thread (#330) if there was evidence that the results are due to p53 itself? I never did understand what you meant by that. And then, more recently, you posed to me the question-- Does the virus selectively replicate in the tumor? And of course, to me, it just looks like the answer is right there in front of me--and even in the message you just posted. But I thought that was the point to onyx-015 all along? "The specific modification of the virus prevents it from replicating efficiently in normal cells." --but that is just off the company website, old news I guess, so I must be missing something? ONYX-015 preferentially targets p53 mutant tumors whereas chemotherapy is often more effective in tumor cells with functional p53. (by the way...I understand MOGN is not about p53, and that Onyx-015 is a totally different animal...naturally keeping an eye on the gene therapy stuff as well had a part in leading me to Onyx.)